Long term Use of Eculizumab for Delayed Hemolytic Transfusion Reaction
in Pediatric Sickle Cell: A Case Report
Abstract
Compliment activation has been implicated in Delayed Hemolytic
Transfusion Reaction (DHTR) in patients with sickle cell disease, and
eculizumab has been reported as an effective treatment for patients with
DHTR. Previously reported patients with SCD and DHTR responded well
after few doses of eculizumab. We report on the long-term use of
eculizumab in a pediatric sickle cell patient with DHTR who had a slow
and less sustained response. Long-term use of eculizumab in this SCD
patient was effective and well tolerated.